Literature DB >> 17200964

Provider roles in the recruitment of underrepresented populations to cancer clinical trials.

Mollie W Howerton1, M Chris Gibbons, Charles R Baffi, Tiffany L Gary, Gabriel Y Lai, Shari Bolen, Jon Tilburt, Teerath Peter Tanpitukpongse, Renee F Wilson, Neil R Powe, Eric B Bass, Jean G Ford.   

Abstract

BACKGROUND: Providers play a vital role in the successful recruitment of underrepresented patients to cancer clinical trials because they often introduce the opportunity of clinical trials. The purpose of the current systematic review was to describe provider-related factors influencing recruitment of underrepresented populations to cancer clinical trials.
METHODS: To find original studies on the recruitment of underrepresented populations to cancer clinical trials, electronic databases from January 1966 to December 2005 were searched; hand-searched titles in 34 journals from January 2003 to January 2006; and reference lists were examined of eligible articles. Title and abstract reviews were conducted to identify relevant studies. Potential articles were then abstracted using a structured instrument and a serial review process by 2 investigators.
RESULTS: Eighteen studies were eligible for review: 13 targeted healthcare providers, 3 targeted patients/participants, and 2 targeted both providers and patients. The study designs included randomized controlled trial, concurrent controlled trial, case-control, descriptive, and qualitative. A lack of available protocols and/or a lack of provider awareness about clinical trials prevented providers from discussing the opportunity of clinical trials in 2 studies. In 14 studies, patient accrual was affected by provider attitudinal barriers relating to patient adherence to the study protocol, patient mistrust of research, patient costs, data collection costs, and/or patient eligibility. Providers' communication methods were barriers in 5 studies and promoters in 1 study.
CONCLUSIONS: A heterogeneous body of evidence suggests that several provider-related factors influence recruitment of underrepresented groups to clinical trials. Future recruitment efforts should address these factors. (c) 2007 American Cancer Society.

Entities:  

Mesh:

Year:  2007        PMID: 17200964     DOI: 10.1002/cncr.22436

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  79 in total

1.  Training Needs of Clinical and Research Professionals to Optimize Minority Recruitment and Retention in Cancer Clinical Trials.

Authors:  Soumya J Niranjan; Raegan W Durant; Jennifer A Wenzel; Elise D Cook; Mona N Fouad; Selwyn M Vickers; Badrinath R Konety; Sarah B Rutland; Zachary R Simoni; Michelle Y Martin
Journal:  J Cancer Educ       Date:  2019-02       Impact factor: 2.037

2.  "The promise of community-based advocacy and education efforts for increasing cancer clinical trials accrual".

Authors:  Margo Michaels; Elisa S Weiss; John A Guidry; Natasha Blakeney; Liz Swords; Brian Gibbs; Samantha Yeun; Bruce Rytkonen; Robert Goodman; S Lisbeth Jarama; Amanda L Greene; Shilpa Patel
Journal:  J Cancer Educ       Date:  2012-03       Impact factor: 2.037

3.  Community health workers' support for cancer clinical trials: description and explanation.

Authors:  Russell K Schutt; Lidia Schapira; Jennifer Maniates; Jessica Santiccioli; Silas Henlon; Judyann Bigby
Journal:  J Community Health       Date:  2010-08

4.  Should criteria for inclusion in cancer clinical trials be expanded?

Authors:  David E Gerber; Sandi L Pruitt; Ethan A Halm
Journal:  J Comp Eff Res       Date:  2015-08       Impact factor: 1.744

5.  Recruitment of African Americans to National Oncology Clinical Trials through a clinical trial shared resource.

Authors:  Debra Wujcik; Steven N Wolff
Journal:  J Health Care Poor Underserved       Date:  2010-02

6.  Training community health workers about cancer clinical trials.

Authors:  Lidia Schapira; Russell Schutt
Journal:  J Immigr Minor Health       Date:  2011-10

7.  Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual.

Authors:  Andrew L Laccetti; Sandi L Pruitt; Lei Xuan; Ethan A Halm; David E Gerber
Journal:  J Natl Cancer Inst       Date:  2015-02-09       Impact factor: 13.506

8.  Cultivating a cycle of trust with diverse communities in practice-based research: a report from PRIME Net.

Authors:  Christina M Getrich; Andrew L Sussman; Kimberly Campbell-Voytal; Janice Y Tsoh; Robert L Williams; Anthony E Brown; Michael B Potter; William Spears; Nancy Weller; John Pascoe; Kendra Schwartz; Anne Victoria Neale
Journal:  Ann Fam Med       Date:  2013 Nov-Dec       Impact factor: 5.166

9.  Survival of women diagnosed with breast cancer and who have survived a previous cancer.

Authors:  Sandi L Pruitt; Hong Zhu; Daniel F Heitjan; Asal Rahimi; Bhumika Maddineni; Anna Tavakkoli; Ethan A Halm; David E Gerber; Danyi Xiong; Caitlin C Murphy
Journal:  Breast Cancer Res Treat       Date:  2021-02-23       Impact factor: 4.872

10.  Unequal burden of disease, unequal participation in clinical trials: solutions from African American and Latino community members.

Authors:  Marvella E Ford; Laura A Siminoff; Elisabeth Pickelsimer; Arch G Mainous; Daniel W Smith; Vanessa A Diaz; Lea H Soderstrom; Melanie S Jefferson; Barbara C Tilley
Journal:  Health Soc Work       Date:  2013-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.